Program
pelacarsen
Also written as “Pelacarsen”, “ISIS 681257” and “Pelacarsen (TQJ230)”.
Its studies are mostly in Cardiovascular Diseases · Atherosclerosis · Hyperlipoproteinemias · Acute Coronary Syndrome · Aortic Valve Stenosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 104 open or running | phase 3since Jul 16, 2019 | Jul 16, 2019 | Feb 3, 2028phase 3 · NCT06813911 |
| Ionis Pharmaceuticals | 60 open or running | phase 2since Jan 31, 2017 | Apr 1, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Apr 1, 2015.
- Jul 16, 2019Novartis's first study: phase 3 study in Cardiovascular DiseasesNew to NovartisNovartis · NCT04023552 · 8,323 enrolled · United States, Argentina, Australia and more
- Aug 4, 2021Phase 1 study in Hepatic ImpairmentNovartis · NCT05026996 · 17 enrolled · United States
- Mar 14, 2022Phase 3 study in Cardiovascular DiseasesNovartis · NCT05305664 · 51 enrolled · Germany
- Apr 13, 2022Phase 1 study in Healthy ParticipantsIonis Pharmaceuticals · NCT05337878 · 29 enrolled · United States
- Dec 2, 2022Phase 2 study in Aortic Valve StenosisNovartis · NCT05646381 · 502 planned · United States, Austria, Belgium and more
- Jun 2, 2023Phase 3 study in HyperlipoproteinemiasNovartis · NCT05900141 · 41 enrolled · Germany
- Feb 12, 2024Phase 3 study in Cardiovascular DiseasesNovartis · NCT06267560 · 422 enrolled · United States, Puerto Rico
- Feb 3, 2025Phase 3 study in AtherosclerosisNovartis · NCT06813911 · 246 enrolled · United States, China, France and more
- Mar 12, 2025Phase 3 study in AtherosclerosisNovartis · NCT06875973 · 599 enrolled · United States, Puerto Rico
- Apr 1, 2026Phase 3 study in Cardiovascular DiseasesNovartis · NCT07517263 · 5,700 enrolled · United States, Argentina, Australia and more
- May 27, 2026Phase 3 study in Acute Coronary SyndromeNovartis · NCT07625306
- Oct 14, 2026Phase 3 study withdrawnStudy stoppedNCT07625306 · “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”
- Oct 14, 2026Primary completion moved from 2028-12-07 to 2029-01-22Date moved laterphase 3 · +2 months · NCT07625306
- Nov 10, 2026Phase 3 study terminatedStudy stoppedNCT05900141 · “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”
Ahead
- Feb 3, 2028Primary completion: phase 3 study in AtherosclerosisNovartis · NCT06813911
- Jan 9, 2030Primary completion: phase 3 study in Cardiovascular DiseasesNovartis · NCT07517263
- Mar 12, 2030Primary completion: phase 2 study in Aortic Valve StenosisNovartis · NCT05646381
- Dec 8, 2030Primary completion: phase 3 study in AtherosclerosisNovartis · NCT06875973
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07625306Acute Coronary Syndrome | 3 | Withdrawn | Novartis | Jan 22, 2029 | 0 |
| NCT07517263Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novartis | Jan 9, 2030 | 5,700 |
| NCT06875973Atherosclerosis · United States, Puerto Rico | 3 | Active, not recruiting | Novartis | Dec 8, 2030 | 599 |
| NCT06813911Atherosclerosis · United States, China, France and more | 3 | Active, not recruiting | Novartis | Feb 3, 2028 | 246 |
| NCT06267560Cardiovascular Diseases · United States, Puerto Rico | 3 | Completed | Novartis | Mar 25, 2026 | 422 |
| NCT05900141Hyperlipoproteinemias · Germany | 3 | Terminated | Novartis | Oct 15, 2026 | 41 |
| NCT05646381Aortic Valve Stenosis · United States, Austria, Belgium and more | 2 | Recruiting | Novartis | Mar 12, 2030 | 502 |
| NCT05337878Healthy Participants · United States | 1 | Completed | Ionis Pharmaceuticals | Dec 18, 2019 | 29 |
| NCT05305664Cardiovascular Diseases · Germany | 3 | Completed | Novartis | Jan 28, 2025 | 51 |
| NCT05026996Hepatic Impairment · United States | 1 | Completed | Novartis | Oct 19, 2022 | 17 |
| NCT04023552Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Completed | Novartis | Jul 16, 2026 | 8,323 |
| NCT03506854Renal Insufficiency · United States, Canada | 1 | Completed | Ionis Pharmaceuticals | Oct 11, 2018 | 16 |
| NCT03426033Cardiovascular Diseases · Canada | 1 | Completed | Ionis Pharmaceuticals | Feb 25, 2018 | 18 |
| NCT03392051Cardiovascular Diseases · Canada | 1 | Completed | Ionis Pharmaceuticals | Mar 18, 2018 | 18 |
| NCT03070782Cardiovascular Diseases · United States, Canada, Denmark and more | 2 | Completed | Ionis Pharmaceuticals | Jul 26, 2018 | 286 |
| NCT02414594Elevated Lipoprotein(a) · Canada | 1 | Completed | Ionis Pharmaceuticals | Feb 2016 | 60 |
How it is read
Names in the registry
- “Pelacarsen”, 5 entries
- “ISIS 681257”, 4 entries
- “Pelacarsen (TQJ230)”, 2 entries
- “TQJ230”, 2 entries
- “Pelacarsen (TQJ230) 80 mg s.c.”, 1 entry
Conditions, from the studies’ own filings
- Cardiovascular Diseases, 7 studies
- Atherosclerosis, 2 studies
- Hyperlipoproteinemias, 1 study
- Acute Coronary Syndrome, 1 study
- Aortic Valve Stenosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.